The blockade of the lateral parabrachial nucleus (LPBN) with GABA A receptor agonist muscimol induces robust hypertonic NaCl and water intake by rats. In the present study we investigated the effects of previous injections of losartan (AT 1 angiotensin receptor antagonist) into the LPBN on 0.3 M NaCl and water intake induced by muscimol injected bilaterally in the same area in fluid replete rats and in rats treated with the diuretic furosemide combined with a low dose of the angiotensin-converting enzyme inhibitor captopril injected subcutaneously. Male Wistar rats with stainless steel cannulas implanted bilaterally into the LPBN were used. Bilateral injections of muscimol (0.5 nmol/0.2 μl, n = 8) into the LPBN in fluid replete rats induced 0.3 M NaCl intake (23.4 ± 4.1 vs. saline: 0.4 ± 0.4 ml/3 h) and water intake (9.3 ± 1.9 vs. saline: 0.7 ± 0.4 ml/3 h) and pre-treatment of the LPBN with losartan (50 μg/0.2 μl) reduced 0.3 M NaCl intake (3.3 ± 2.5 ml/3 h) and water intake (4.0 ± 2.9 ml/3 h) induced by muscimol. In rats treated with furosemide + captopril, pretreatment with losartan into the LPBN attenuated the increase of 0.3 M NaCl intake produced by muscimol (12.8 ± 5.3, vs. saline + muscimol: 36.7 ± 6.7 ml/3 h) without changing water intake. Therefore, the results suggest that deactivation of LPBN inhibitory mechanisms by muscimol injections into the LPBN is facilitated by endogenous angiotensin II acting on AT 1 receptors in the LPBN, which drives rats to ingest large amounts of hypertonic NaCl. 
Introduction
Important mechanisms for the control of sodium and water intake are present in the lateral parabrachial nucleus (LPBN), a pontine structure located dorsolaterally to the superior cerebellar peduncle (Andrade et al., 2006; Callera et al., 2005; De Luca et al., 2003; De Oliveira et al., 2007; Menani et al., 2002; Menani and Johnson, 1995) . The LPBN is reciprocally connected to forebrain areas, such as the paraventricular nucleus of the hypothalamus (PVN), the central nucleus of the amygdala (CeA) and the median preoptic nucleus (MnPO), and to medullary regions, like the area postrema (AP) and the medial portion of the nucleus of the solitary tract (mNTS) (Ciriello et al., 1984; Fulwiler and Saper, 1984; Herbert et al., 1990; Jhamandas et al., 1992 Jhamandas et al., , 1996 Norgren, 1981) . Therefore, the LPBN may convey signals that ascend from AP/mNTS to the forebrain areas that regulate fluid and electrolyte balance and related behaviors like water and sodium intake. Numerous neurotransmitter systems have implicated the LPBN in the control of sodium intake. For example, bilateral LPBN injections of methysergide, a serotonergic receptor antagonist, increase hypertonic NaCl intake induced by angiotensin II (ANG II) administered intracerebroventricularly (i.c.v.) or into the subfornical organ (SFO), by 24 h of water deprivation, by 24 h of sodium depletion or by deoxycorticosterone acetate (DOCA) (De Gobbi et al., 2001; Menani et al., 1996 Menani et al., , 1998a Menani et al., , 2000 Menani and Johnson, 1995) . Blockade of cholecystokinin (CCK) or serotonin receptors or activation of α 2 -adrenergic receptors in the LPBN enhances NaCl intake by rats injected subcutaneously with the diuretic furosemide (FURO) combined with the angiotensin converting enzyme inhibitor captopril (CAP) (Andrade et al., 2004; De Gobbi et al., 2001; Menani et al., 1996 Menani et al., , 1998b . The blockade of LPBN neurons with bilateral injections of the GABA A agonist muscimol induces robust ingestion of hypertonic NaCl and slight ingestion of water in fluid replete rats and increases FURO + CAP-and 24 h sodium depletion-induced sodium intake, suggesting that a GABAergic mechanism present in LPBN is involved in the control of sodium intake (Callera et al., 2005; De Oliveira et al., 2007) .
The cardiovascular, neuroendocrine and ingestive effects of ANG II acting centrally are mediated mainly by angiotensin type 1 (AT 1 ) receptors located in different areas of the central nervous system, such as the LPBN, anterior hypothalamic area (AHA), amygdala, SFO, rostral and caudal ventrolateral medulla and NTS (Fitzsimons, 1998; Fregly and Rowland, 1991; Mckinley et al., 1996; Rowland et al., 1992; Thunhorst and Fitts, 1994) . The nonpeptide antagonist losartan selectively binds on AT 1 receptors (Chiu et al., 1989) .
Studies using whole cell voltage-clamp techniques have suggested that ANG II acting on AT 1 receptors may modulate GABAergic synaptic transmission and produce opposite effects, depending on whether pre-or post-synaptic AT 1 receptors are activated (Henry et al., 2009; Li et al., 2003; Li and Pan, 2005; Xing et al., 2009) . It has been suggested that ANG II acting on pre-synaptic AT 1 receptors reduces GABA release and decreases the amplitude of evoked GABAergic inhibitory post-synaptic currents (IPSCs) (Li et al., 2003; Li and Pan, 2005; Xing et al., 2009 ). In contrast, it was shown that endogenous ANG II acting on post-synaptic AT 1 receptors increases IPSCs in sodium-sensitive neurons in the median preoptic nucleus (MnPO) (Henry et al., 2009) . According to these studies, treatment with ANG II increased the firing of PVN neurons that project to the rostroventrolateral medulla (RVLM) and decreased the amplitude of evoked GABAergic IPSCs and the frequency of miniature IPSCs, effects blocked by the AT 1 receptor antagonist losartan (Li et al., 2003; Li and Pan, 2005) . Treatment with ANG II also decreased the amplitude of evoked IPSCs and the frequency of miniature IPSCs in neurons of the dorsolateral periaqueductal gray, an effect blocked by losartan, but not by the AT 2 antagonist PD123319 (Xing et al., 2009) . Treatment with ANG II had no effect on excitatory post synaptic currents in the PVN neurons or in the dorsolateral periaqueductal gray (Li et al., 2003; Li and Pan, 2005; Xing et al., 2009) . In contrast, another study showed that the amplitude of the IPSCs in the MnPO was reduced by the treatment with losartan, suggesting a post synaptic action of endogenous ANG II that facilitated the effect of the GABAergic input to the MnPO (Henry et al., 2009) .
Considering the effects of the activation of GABA A receptors in the LPBN on hypertonic NaCl and water intake (Callera et al., 2005; De Oliveira et al., 2007) and the results of previous studies showing that AT 1 receptor activation may modulate the action of the GABAergic mechanisms (Henry et al., 2009; Li et al., 2003; Li and Pan, 2005; Xing et al., 2009) , in the present study we investigated the effects of injections of the specific AT 1 receptor antagonist, losartan, into the LPBN on water and hypertonic NaCl intake induced by the activation of GABA A receptors by muscimol injections into the LPBN in fluid replete or FURO + CAP-treated rats. , 2006; Callera et al., 2005; De Gobbi et al., 2001; De Luca et al., 2003; De Oliveira et al., 2007) . In some rats, injections spread to the brachium (superior cerebellar peduncle), or slightly ventral to this structure, reaching the dorsal portions of the medial parabrachial nucleus (MPBN) uni-or bilaterally. There was no difference in the effects if the injections were restricted to the LPBN or if they spread to the ventral structures described above. 
Results

Histological analysis
2.2.
Effects of combined injections of losartan and muscimol into the LPBN on water and 0.3 M NaCl intake in fluid replete rats ANOVA showed significant differences between treatments for 0.3 M NaCl [F(3, 21) = 20.7; P < 0.001] and water intake [F(3, 21) = 9.05; P < 0.001] in fluid replete rats that received injections of saline or losartan combined with injections of saline or muscimol into the LPBN (Fig. 2) .
In two-bottle tests, bilateral injections of muscimol (0.5 nmol/0.2 μl at each site, n = 8) into the LPBN in fluid replete rats induced 0.3 M NaCl intake (23.4 ± 4.1 ml/3 h, vs. saline + saline: 0.4 ± 0.4 ml/3 h, Figs. 2A and B) and water intake (9.3 ± 1.9 ml/3 h, vs. saline + saline: 0.7 ± 0.4 ml/3 h, Figs. 2C and D) . Previous injections of the AT 1 receptor antagonist losartan (50 μg/0.2 μl each site) into the LPBN reduced the effects of muscimol (0.5 nmol/0.2 μl) injected in the same area on 0.3 M NaCl intake (3.3 ± 2.5 ml/3 h, Figs. 2A and B) and water intake (4.0 ± 2.9 ml/3 h, Figs. 2C and D).
The ingestion of 0.3 M NaCl and water after bilateral injections of muscimol into the LPBN in replete rats was significantly different from those after saline injected into the LPBN (control) from 120 min to the end of the test (180 min) and the pre-treatment with losartan injected into the LPBN reduced the ingestion of 0.3 M NaCl and water in the same period (Figs. 2A and C).
Losartan injected alone into the LPBN did not affect water or 0.3 M NaCl intake.
2.3.
Effects of combined injections of losartan and muscimol into the LPBN on FURO + CAP-induced 0.3 M NaCl and water intake ANOVA showed significant interactions between treatments and times for 0.3 M NaCl intake [F(18, 126)= 9.5; P < 0.001] and for water intake [F(18, 126) = 4.1; P < 0.001] induced by FURO+ CAP in rats that received injections of saline or losartan combined with injections of saline or muscimol into the LPBN (Fig. 3) .
Bilateral injections of muscimol (0.5 nmol/0.2 μl at each site, n = 8) into the LPBN increased FURO + CAP-induced 0.3 M NaCl intake from 120 min to the end of the test (36.7 ± 6.7 ml/3 h, vs. saline + saline: 7.2 ± 3.3 ml/3 h) (Figs. 3A and B). Losartan (50 μg/0.2 μl at each site) injected into the LPBN reduced the effects of muscimol on 0.3 M NaCl intake from 120 min to the end of the test (12.8 ± 5.3 ml/3 h) (Figs. 3A and B). Losartan injected alone into the LPBN produced no change in FURO + CAP-induced 0.3 M NaCl intake.
A tendency toward the reduction of FURO + CAP-induced water intake at 30 and 60 min of the test occurred after injections of muscimol into the LPBN, an effect partially reversed by pre-treatment with losartan ( Fig. 3C ). Losartan injected alone into the LPBN produced no significant change in FURO + CAP-induced water intake compared to the treatment with saline (Figs. 3C and D). However, opposite effects on water intake after losartan and muscimol were injected alone into the LPBN resulted in a significant difference between these treatments at 60 min of the test (Fig. 3C ).
Specificity of injections into the LPBN on water and 0.3 M NaCl intake
Results from rats that received injections outside the LPBN (misplaced injections) were analyzed to show that the effects Fluid replete rats 0.3 M NaCl intake Water intake (ml/3 h) (ml/3 h) Saline + saline 1.7 ± 0.3 3.4 ± 0.3 Saline + muscimol 3.2 ± 0.7 2.5 ± 0.5 Losartan + muscimol 2.7 ± 0.6 2.8 ± 0.5 Losartan + saline 1.6 ± 0.2 1.5 ± 0.3 FURO + CAP-treated rats Saline + saline 4.3 ± 1.3 7.1 ± 2.5 Saline + muscimol 7.8 ± 2.8 6.0 ± 2.3 Losartan + muscimol 9.4 ± 5.1 5.4 ± 2.5 Losartan + saline 3.6 ± 1.8 2.6 ± 1.0
Values are means ± S.E.M. n = 6 rats/group. Losartan (50 μg/0.2 μl); muscimol (0.5 nmol/0.2 μl).
on 0.3 M NaCl and water intake were due to a specific activation of GABA A receptors in the LPBN. Bilateral injections of muscimol or losartan alone or of muscimol combined with losartan in sites outside the LPBN did not affect water and 0.3 M NaCl intake in fluid replete rats or FURO + CAP-treated rats (Table 1) . ANOVA showed no significant differences between treatments for 0.3 M NaCl intake [F(3, 12 
Discussion
Similar to previous results (Callera et al., 2005; De Oliveira et al., 2007) , the present study shows that bilateral injections of muscimol (GABA A receptor agonist) into the LPBN induce hypertonic NaCl and water ingestion in fluid replete rats (untreated rats) and increase 0.3 M NaCl intake in FURO + CAPtreated rats. The involvement of GABA A receptors of the LPBN in the control of water and NaCl intake is supported by a previous study showing that the GABA A receptor antagonist bicuculline injected into the LPBN completely blocked water and hypertonic NaCl intake induced by muscimol, which suggests that muscimol activates LPBN GABA A receptors to increase sodium intake (Callera et al., 2005) . The present results extend the conclusions of the previous study by showing that pretreatment of the LPBN with bilateral injections of the nonpeptide AT 1 receptor antagonist losartan reduce water and 0.3 M NaCl intake caused by muscimol injected into the same site in fluid replete rats, as well as the increase in 0.3 M NaCl produced by muscimol injected bilaterally into the LPBN in FURO + CAP-treated rats. Injections of losartan alone into the LPBN did not change water or 0.3 M NaCl intake by untreated rats or FURO + CAP-treated rats.
Results from rats with misplaced injections confirm that muscimol effects on water and 0.3 M NaCl intake are specific to the LPBN. The results also suggest that angiotensinergic mechanisms in the LPBN are essential for the dipsogenic and natriorexigenic responses induced by the blockade of LPBN neurons with muscimol in fluid replete rats or the increase in the natriorexigenic responses produced by muscimol injected into the LPBN in FURO + CAP-treated rats. Pretreatment with losartan into the LPBN reduced muscimol effects on water and/or NaCl intake by fluid replete or FURO + CAP-treated rats. Therefore, if endogenous GABA release in the LPBN was important for FURO + CAP-induced water and sodium intake, similar effects would be expected when losartan alone was injected in FURO + CAP-treated rats. However, injections of losartan alone did not modify FURO + CAP-induced water or NaCl intake, suggesting that GABA release or its interaction with activated AT 1 receptors in the LPBN is not essential for sodium or water intake induced by FURO + CAP. Perhaps any reduction of GABA effects by losartan was compensated for by changes in the release of other neurotransmitters in the LPBN like serotonin, CCK, corticotropin-releasing hormone (CRF), glutamate, opioids or noradrenaline that also modulate water and sodium intake (De Castro e Silva et al., 2006; De Oliveira et al., 2008; De Gobbi et al., 2009; Gasparini et al., 2009; Menani et al., 1996; Menani and Johnson, 1998) .
AT 1 receptors and ANG II terminals are present in the LPBN (Lenkei et al., 1997; Mckinley et al., 2002) ; however, we found no clear evidence in the literature of ANG II effects in the LPBN. The present results suggest that ANG II acting on AT 1 receptors in LPBN is necessary for the full effects of muscimol injected into the LPBN on water and sodium intake. The treatment with FURO + CAP increases ANG II centrally (Thunhorst and Johnson, 1994). However, it is possible that activation of AT 1 receptors by baseline levels of ANG II in fluid replete rats is sufficient to facilitate the increase in water and sodium intake produced by muscimol in the LPBN. On the other hand, although there is no evidence that injections of muscimol into the LPBN increase ANG II levels, the present results do not allow us to exclude the possibility of an increase in central or peripheral levels of ANG II due to muscimol injections into the LPBN. The ingestion of sodium after muscimol injections into the LPBN takes at least 1 h to start, which is time enough for changes in the levels of ANG II within the LPBN that may intensify the effects of muscimol on LPBN neurons, a step necessary for the release of sodium intake.
The cardiovascular, neuroendocrine and ingestive effects of ANG II acting centrally are mediated mainly by AT 1 receptors (Fitzsimons, 1998; Kirby et al., 1992; Mckinley et al., 1996; Rowland et al., 1992; Saavedra, 1994; Thunhorst and Fitts, 1994) . For example, ingestion of water and NaCl is suggested to depend on the action of circulating ANG II on circumventricular organs like the SFO and OVLT (Krause et al., 2008; Morris et al., 2002; Thunhorst and Fitts, 1994) . At the same time, AT 1 receptors have a role in mediating an enhanced sodium intake produced by blockade of LPBN inhibitory mechanisms with injections of the serotonergic antagonist methysergide (Colombari et al., 1996; Menani et al., 1998b) . More specifically, injections of methysergide into the LPBN combined with treatments that increase ANG II centrally or peripherally, such as FURO + CAP sc, isoproterenol or acute (1 h previous) treatment with FURO, also produce robust ingestion of 0.3 M NaCl (Menani et al., 1998a (Menani et al., , 2000 . Whereas treatment with FURO + CAP alone induces significant ingestion of NaCl, sc treatments with isoproterenol or acute furosemide do not produce significant ingestion of NaCl, despite increases in ANG II signaling, unless LPBN inhibitory mechanisms are deactivated. Therefore, sodium intake does not always increase even with increased levels of ANG II. However, if the LPBN inhibitory mechanisms are deactivated, then ANG IIinduced sodium and water intake is strongly facilitated.
In addition to methysergide, the blockade of other neurotransmitters in the LPBN like CCK, CRF or glutamate, or activation of α 2 adrenoceptors with noradrenaline or moxonidine, deactivate LPBN inhibitory mechanisms and increase sodium and water intake induced by treatment with FURO + CAP (Andrade et al., 2004; De Castro e Silva et al., 2006; De Gobbi et al., 2001; Gasparini et al., 2009; Menani et al., 1996; Menani and Johnson, 1998) . The blockade of these neurotransmitters or activation of α 2 adrenoceptors in the LPBN produces no sodium or water intake in fluid replete rats, which might suggest that sodium intake easily arises only when facilitatory mechanisms are activated and inhibitory mechanisms are simultaneously deactivated. However, in contrast to the blockade of the other neurotransmitters or α 2 adrenoceptor activation, either opioid (β endorphin) or GABAergic (muscimol) activation of the LPBN induces robust ingestion of water and 0.3 M NaCl in fluid replete rats, suggesting that the deactivation of LPBN inhibitory mechanisms alone is sufficient to drive rats to ingest hypertonic NaCl (Callera et al., 2005; De Oliveira et al., 2007 . Substantial ingestion of sodium starts~2-3 h after muscimol injections into the LPBN in untreated rats (Callera et al., 2005, present results) . The present results also show an increased sodium intake 2-3 h after injections of muscimol into the LPBN in FURO + CAP-treated rats.
Injections of muscimol into the LPBN produces a small increase on arterial pressure and non-significant effects on renal excretion in fluid replete rats (Callera et al., 2005; De Oliveira et al., 2007) , which suggests that sodium intake produced by muscimol into the LPBN is not secondary to decreases in blood pressure or an increase in urinary sodium excretion. Rather, ingestion of hypertonic NaCl solutions increases the activity of LPBN neurons, suggesting that the LPBN can be activated by taste and/or visceral stimuli (Franchini and Vivas, 1999; Yamamoto et al., 1993) . Signals from volume, taste and other visceral receptors that may participate in the control of water and sodium intake reach the AP/mNTS before ascending to the LPBN which, in turn, sends projections to forebrain areas involved in the control of fluid and electrolyte balance, such as the SFO, MnPO, PVN and amygdala (Ciriello et al., 1984; Jhamandas et al., 1992; Krukoff et al., 1993; Norgren, 1981; Shapiro and Miselis, 1985) . A recent study showed that bilateral lesions of the CeA abolished water and 0.3 M NaCl intake produced by the blockade of LPBN neurons with muscimol in fluid replete rats, suggesting that facilitatory mechanisms present in the CeA are essential for the dipsogenic and natriorexigenic responses induced by muscimol injected into the LPBN (Andrade-Franzé et al., 2010) . Consistent with this idea, the CeA contains AT 1 receptors and has been proposed as a possible site of interaction between ANG II and mineralocorticoids to stimulate sodium appetite (Galaverna et al., 1992; McKinley et al., 2002) .
AT 1 receptors are present in different areas of the brain, including the LPBN (Fitzsimons, 1998; Mckinley et al., 1996) . Modulation of GABAergic neurotransmission by ANG II depends upon whether the AT 1 receptors are located pre-or postsynaptically. Activation of pre-synaptic AT 1 receptors reduce the effects of GABAergic activation, whereas activation of postsynaptic AT 1 receptors increase the effects (Henry et al., 2009; Li et al., 2003; Li and Pan, 2005; Xing et al., 2009 ). The present results show that blockade of AT 1 receptors by the injection of losartan into the LPBN reduces hypertonic NaCl and water intake stimulated by the activation of LPBN GABA A receptors with muscimol injected in the same area in fluid replete or in FURO+ CAP-treated rats. Thus, it appears that ANG II acts on post-synaptic AT 1 receptors in the LPBN to enhance the activation of GABA receptors with muscimol via a mechanism similar to that described in the MnPO (Henry et al., 2009) . Taken together, these results suggest that interactions of angiotensinergic and GABAergic mechanisms in the LPBN are important to stimulate sodium intake. In other words, the action of ANG II on AT 1 receptors in the LPBN is important for the inhibition of LPBN neurons, thereby facilitating sodium intake produced by activation of GABAergic mechanisms in the LPBN.
4.
Experimental procedures
Animals
Male Wistar rats weighing 290-310 g were used. The animals were housed in individual stainless steel cages with free access to standard sodium diet (Guabi Rat Chow, Paulinia, SP, Brazil), water and 0.3 M NaCl solution. The positions of the bottles containing water and 0.3 M NaCl were rotated daily to avoid place preference. Room temperature was maintained at 23 ± 2°C and humidity was maintained at 55 ± 10% on a 12:12 light-dark cycle with light onset at 07:30 AM. The procedures were approved by the Institutional Ethical Committee for Animal Care from the School of Dentistry, UNESP, Araçatuba, Brazil (Proc. CEEA no. 986/2007) and followed the recommendations from the Brazilian College of Animal Experimentation (COBEA) and the American National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH publications No. 80-23, 1996, USA) .
All efforts were made to minimize animal discomfort and the number of animals used.
Cerebral cannulas
Rats were anesthetized with subcutaneous (sc) ketamine (80 mg/kg of body weight, Cristália, Brazil) combined with xylazine (7 mg/kg of body weight, Agener, Brazil) and placed in a stereotaxic instrument (Kopf, USA). The skull was leveled between bregma and lambda. Stainless steel guide-cannulas (12 × 0.6 mm o.d.) were implanted bilaterally into the LPBN using the following coordinates: 9.2 mm caudal to bregma, 2.2 mm lateral to the midline, and 3.8 mm below the dura mater (Paxinos and Watson, 1997) . The tips of the cannulas were positioned 2 mm above each LPBN. The cannulas were fixed to the cranium using dental acrylic resin and jeweler screws and were filled with 30-gauge metal obturators between tests. After the surgery, the rats received intramuscular injections of the analgesic cetoprophen 1% (0.03 ml) and a prophylactic dose of the antibiotic penicillin (30,000 IU). Rats were allowed to recover for 5 days before starting ingestion tests and during this period they had free access to standard sodium diet, water and 0.3 M NaCl solution.
Injections into the LPBN
Bilateral injections into the LPBN were made using 5-μl Hamilton syringes connected by polyethylene tubing (PE-10) to 30-gauge injection cannulas. At the time of testing, obturators were removed and the injection cannula (2 mm longer than the guide cannula) was carefully inserted into the guide cannula. For bilateral injections, the first injection was performed on one side, the needle was removed and repositioned on the contra lateral side, and then the second injection made. Therefore injections were made~1 min apart. The injection volume into the LPBN was 0.2 μl on each site. The obturators were replaced after the injections, and the rats were placed back into their cages.
Drugs
Furosemide (FURO) (Sigma-Aldrich, Saint Louis, MO, USA) was dissolved in alkaline saline (pH adjusted to 9.0) and administered sc at the dose of 10 mg/kg of body weight (bw). Captopril (CAP) (Sigma-Aldrich, Saint Louis, MO, USA), was dissolved in 0.15 M NaCl and administered sc at the dose of 5 mg/kg of bw. Muscimol HBr and losartan potassium (Sigma-Aldrich, Saint Louis, MO, USA) were dissolved in 0.15 M NaCl. The dose of muscimol used in the present study was the same as that used in previous studies that investigated the effects of muscimol injected into the LPBN on water and 0.3 M NaCl intakes (Callera et al., 2005; De Oliveira et al., 2007) . This dose of muscimol produces a long-lasting action (at least for 1 h) when injected into the LPBN (Callera et al., 2005) . The dose of losartan was based on previous studies that have tested the effects of central injections of losartan on water and sodium intake and on the pressor response to ANG II (Grippo et al., 2002; Menani et al., 2004) . The dose of losartan used is effective for at least 2 h (Menani et al., 2004) .
4.5.
Water and 0.3 M NaCl intake by fluid replete rats
The rats were tested in their home cages. Water and 0.3 M NaCl were provided from burettes with 0.1-ml divisions that were fitted with metal drinking spouts. Food was not available during the tests. Measurements were taken at 30-min intervals for 180 min, starting 10 min after bilateral injections of muscimol (0.5 nmol/0.2 μl) or saline (0.2 μl) into the LPBN. Fluid replete rats that received no pre-treatment (n = 14), were tested for the effects of the combination of losartan and muscimol injections into the LPBN on water and 0.3 M NaCl intake. Losartan (50 μg/0.2 μl) was injected into the LPBN 10 min before muscimol (0.5 nmol/0.2 μl). These rats were submitted to four tests and received the following combinations of treatments into the LPBN: saline + saline, saline + muscimol, losartan + muscimol and losartan + saline. In each test, the group of rats was divided in two and half of the group received one of the combination of treatments listed above, while the remaining animals received another combination of treatments into the LPBN. The sequence of the treatments was randomized for each rat so that, at the end of testing, rats had received all four treatments. A recovery period of at least 2 days was allowed between tests.
4.6.
Water and 0.3 M NaCl intake by FURO + CAP-treated rats
Another group of rats (n = 14) was used to test water and 0.3 M NaCl intake induced by treatment with FURO + CAP sc. On the day of the experiment, food, water and 0.3 M NaCl were removed and the cages were rinsed with water. Rats received sc injections of the diuretic FURO (10 mg/kg bw) plus CAP (5 mg/kg bw) as described previously (Callera et al., 2005; De Gobbi et al., 2001; Menani et al., 1996; Thunhorst and Johnson, 1994) . One hour after FURO + CAP treatment, burettes with water and 0.3 M NaCl solution were returned and measurements were taken at 30-min intervals for 180 min (sodium appetite test). Ten minutes before access to water and 0.3 M NaCl, rats received bilateral injections of muscimol (0.5 nmol/0.2 μl) or saline into the LPBN. Bilateral injections of losartan (50 μg/0.2 μl) or saline into the LPBN were performed 10 min before the injections of muscimol or saline into the LPBN. In each experimental session, the group of rats was divided in two and each half of the group received one of the four treatments in the LPBN: saline + saline, saline + muscimol, losartan + muscimol and losartan + saline. The sequence of the treatments was in a randomized order so that at the end of testing, rats had received all four treatments. A recovery period of at least 3 days was allowed between experimental sessions. The order of treatments was randomized because repeated FURO + CAP injections enhances stimulated and spontaneous NaCl intake (Pereira et al., 2010) .
Histology
At the end of the experiments, the animals received bilateral injections of 2% Evans blue dye solution (0.2 μl/injection site) into the LPBN. They were then deeply anesthetized with sodium thiopental (CRISTALIA, Itapira, SP, Brazil, 80 mg/kg of body weight) and perfused transcardially with saline followed by 10% formalin. The brains were removed, fixed in 10% formalin, frozen, cut in 60 μm sections, stained with Giemsa, and analyzed by light microscopy to confirm the injection sites in the LPBN.
Data analysis
The results are reported as means ± S.E.M. Water and 0.3 M NaCl intake was analyzed by two-way analysis of variance (ANOVA) with repeated measures for both factors (treatments and times), followed by Newman-Keuls post hoc test. Differences were considered significant at P < 0.05. The software used for the analysis was SigmaStat for Windows, version 2.03 from SPSS Inc.
